Stock NVCR NOVOCURE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX
Other stock markets
 10:35:57 2025-01-14 am EST 		5-day change 1st Jan Change
27.04 USD -1.24% Intraday chart for NovoCure Limited -5.58% -8.09%
Dec. 02 HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating MT
Dec. 02 NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint MT

Press Releases

Search
See the results
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
Jan. 13
 BU
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
Jan. 06
 AQ
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
Jan. 03
 BU
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy for Pancreatic Cancer
Dec. 03
 AQ
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy for Pancreatic Cancer
Dec. 03
 AQ
Novocure : Announces Positive Topline Results from Phase 3 PANOVA 3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Form 8 K
Dec. 02
 PU
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
Dec. 02
 BU
Novocure to Participate in Upcoming Investor Conferences
Nov. 27
 BU
FDA Approves Novocure's Innovative HFE Transducer Arrays for Use with Optune Gio for Glioblastoma
Nov. 22
 AQ
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields Therapy in Glioblastoma
Nov. 22
 AQ
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
Nov. 21
 BU
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
Nov. 21
 BU
NovoCure: Q3 Earnings Snapshot
24-10-30
 AQ
Novocure : Reports Third Quarter 2024 Financial Results Form 8 K
24-10-30
 PU
Novocure Appoints Christoph Brackmann as Chief Financial Officer
24-10-30
 BU
Novocure Reports Third Quarter 2024 Financial Results
24-10-30
 BU
FDA Approves Novocure's Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer
24-10-16
 AQ
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
24-10-15
 BU
NovoCure : FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non Small Cell Lung Cancer Form 8 K
24-10-15
 PU
Novocure to Report Third Quarter 2024 Financial Results
24-10-01
 BU
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields Therapy
24-09-10
 AQ
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
24-09-09
 BU
Novocure Announces Planned CEO Transition
24-09-03
 BU
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
24-08-28
 BU
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
24-08-14
 BU
Become a member to access more news.
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NVCR Stock
  4. News NovoCure Limited
  5. Press Releases